All In Biotech

Drug Trial Radar · NCT07002320

Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer

ASpiRE: A Proof-of-mechanism and Proof-of-concept Clinical Trial Evaluating the Safety, Tolerability, Biological and Anti-tumour Activity of Apalutamide With Dual CXCR1 and CXCR2 Blockade by SX-682 for Men Suffering From Metastatic Castration-resistant Prostate Cancer (mCRPC)

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

78

Planned (sponsor's estimate)

Start

Apr 28, 2025

Primary completion

Oct 2029

Study completion Oct 2029

Sponsor

Lead sponsor
Institute of Cancer Research, United KingdomAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Prostate Cancer UK; Janssen Pharmaceutica N.V., Belgium; Oncology Institute of Southern Switzerland; Syntrix Biosystems, Inc.; Royal Marsden NHS Foundation Trust; Cambridge University Hospitals NHS Foundation Trust; Belfast Health and Social Care Trust; Institute of Oncology Research (IOR)
First posted
Jun 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

ASpiRE will investigate the effect of the drug SX-682 in combination with Apalutamide in men suffering from metastatic castration-resistant prostate cancer (mCRPC).

Conditions

  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC)

Interventions

  • SX-682Drug

    SX-682 is supplied as 100mg film coated tablets.

  • ApalutamideDrug

    Apalutamide is supplied as 60mg film coated tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biologically active and tolerable dose rangeTime frame: From start of treatment to end of Cycle 2 Day 1 (each cycle is 28 days)
  2. Anti-tumour activity of SX-682 when administered with ApalutamideTime frame: 24 months

Locations

4 sites in 2 countries. Site status is shown where the registry gives one.

  • Oncology Institute of Southern Switzerland

    Bellinzona, Switzerland · Recruiting

  • Belfast Health and Social Care Trust

    Belfast, United Kingdom · Recruiting

  • Cambridge University Hospitals NHS Foundation Trust

    Cambridge, United Kingdom · Recruiting

  • The Royal Marsden NHS Foundation Trust - Drug Development Unit

    Sutton, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.